RDInvesting Provides Investors with Free In-Depth Equity Reports on DVAX, MNOV, NKTR and PLX
Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at www.RDInvesting.com and get exclusive access to our numerous stock reports and market updates.
Dynavax Technologies Corporation (NASDAQ: DVAX) shares increased 8.65 percent to close at $1.13 a share Wednesday. The stock traded in between $1.01 and $1.14 on volume of 6.76 million shares traded. The company announced that its Chief Scientific Officer, Dr. Robert L. Coffman, has awarded the 2013 Novartis Prize for Basic Immunology. Shares of Dynavax Technologies have fallen approximately 60.35 percent year-to-date.
Find out more about Dynavax Technologies including full access to the free equity report at:
www.RDInvesting.com/DVAX
MediciNova, Inc. (NASDAQ: MNOV) shares soared 31.13 percent to close at $3.37 a share Wednesday. The stock traded between $2.61 and $3.85 on volume of 3.37 million shares traded. The company announced that it presented preliminary results from a Phase 1b study of MN-166 in methamphetamine addiction at the 75th Annual Meeting of the College on Problems of Drug Dependence. Shares of MediciNova have gained approximately 105 percent year-to-date.
Find out more about MediciNova including full access to the free equity report at:
www.RDInvesting.com/MNOV
Nektar Therapeutics (NASDAQ: NKTR) shares spiked 11.62 percent to close at $10.95 a share Wednesday. The stock traded in between $9.54 and $11.07 on volume of 2.80 million shares traded. The company has reported positive top-line results from a human abuse liability (HAL) study for NKTR-181. Shares of Nektar Therapeutics have gained approximately 47.8 percent year-to-date.
Find out more about Nektar Therapeutics including full access to the free equity report at:
www.RDInvesting.com/NKTR
Protalix BioTherapeutics Inc. (NYSEMKT: PLX) shares increased 2.95 percent to close at $5.23 a share Wednesday. The stock traded between $5.10 and $5.45 on volume of 1.31 million shares traded. Analysts at Zacks have recently upgraded the company’s rating to “outperform” from “neutral”.
Find out more about Protalix BioTherapeutics including full access to the free equity report at:
www.RDInvesting.com/PLX
Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Research Driven Investing has no financial relationship with any company whose stock is mentioned in this release.
Contact:
Research Driven Investing
info@rdinvesting.com